Isabeau Thijs

Isabeau Thijs

Auto-generated profile, based on publicly available information

Isabeau Thijs

Medtronic Diabetes, Medtronic International Trading Sàrl Tolochenaz Switzerland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
ITIsabeau Thijs
Isabeau Thijs
LFLibera Fresiello
Libera Fresiello
WOWouter Oosterlinck
Wouter Oosterlinck
PSPeter Sinnaeve
Peter Sinnaeve
FRFilip Rega
Filip Rega
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Wearable technology is finding its way in clinical practices. Physical Activity (PA) describes patient’s functional status after cardiac surgery and in remote monitoring by use of PA trackers. Objective: The aim of this work is to assess the usability of a wearable fitness tracker, to monitor patients who underwent coronary artery bypass surgery, by either the conventional Off-Pump procedure (OPCAB) or robotically assisted CABG (RA-MIDCAB). We hypothesized a faster recovery of functional status after RA-MIDCAB in the first weeks after discharge. Methods: Patients undergoing RA-MIDCAB or OPCAB were included. Each patient received a Fitbit Charge Heart Rate PA tracker (Fitbit Inc., San Francisco, CA, USA) following discharge. Rehabilitation progress was assessed by measuring the number of steps and physical activity level (PAL) daily. PAL was calculated as energy expenditure divided by basic metabolic rate. Results: 10 RA-MIDCAB patients with a median age of 68 (IQR: [60;76]) and 12 OPCAB patients with a median age of 69 (IQR: [65;76]) were included. Baseline characteristics were comparable except for BMI (RA-MIDCAB: 26 Kg/m² [24;27] versus OPCAB: 29 Kg/m² [27;31]; P<0.001, respectively). Intubation time (P<0.05) was significantly lower in the RA-MIDCAB group. A clear trend, although not statistically significant, was observed towards a higher number of steps in RA-MIDCAB patients in the first week following discharge. Conclusions: Wearable PA trackers can describe functional status in a cardiac rehabilitation setting after surgery. RA-MIDCAB patients have an advantage in recovery in the first weeks of revalidation reflected by the number of steps and PAL, measured by the Fitbit Charge HR, compared to OPCAB patients. However, unsupervised assessment of daily PA varied greatly and this could involve consequences for the use of these trackers as research tools. Clinical Trial: S59757

4 February 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
VSVittorino Smaniotto
Vittorino Smaniotto
SHSimon Heller
Simon Heller
DODavid O'NEal
David O'NEal
JJJohan Jendle
Johan Jendle
TCTali Cukierman-Yaffe
Tali Cukierman-Yaffe
OCOhad Cohen
Ohad Cohen
Aims: Large‐scale studies on the effectiveness of automated insulin delivery (AID) systems in older people with type 1 diabetes are still limited. A multinational, retrospective, real‐world study was conducted to examine the performance of the MiniMed™ 780G advanced hybrid closed‐loop system in users with type 1 diabetes aged ≥56 years compared with those aged 16–55 years. Materials and Methods: Data from 35 366 MiniMed™ 780G system users aged 16–55 years and 7415 users aged ≥56 years were included. The main outcome was time in range 70–180 mg/dL (TIR); other continuous glucose monitoring (CGM) metrics were also assessed. Results: Across all users, mean TIR was 77.1% for users aged ≥56 years and 73.1% for those aged 16–55 years (Δ4.0, 95% confidence interval [CI]: 3.8–4.2, p <0.0001). In users employing the optimal system settings (i.e., Glucose Target: 100 mg/dL; active insulin time: 2 h), mean TIR was 81.9% in older and 79.7% in younger users (Δ2.2, 95% CI: 1.5–2.9, p <0.0001). Across all users, mean time below range 70% without increasing hypoglycaemia risk. Users employing optimal settings showed the best outcomes. The system performed as well as or better than in younger users. These findings support the case that more stringent TIR targets can be achieved safely.

12 March 2025 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
ITIsabeau Thijs
Isabeau Thijs
AAArcelia Arrieta
Arcelia Arrieta
JCJavier Castañeda
Javier Castañeda
MJMichael Joubert
Michael Joubert
Francesco GiorginoFrancesco Giorgino
Francesco Giorgino
OCOhad Cohen
Ohad Cohen
Background: Type 2 diabetes (T2D) is a phenotypically heterogeneous disease. The use of insulin is required in a significant portion of people with T2D, despite recent developments in antidiabetic medications. This study analyzes glycemic outcomes in automated insulin delivery (AID) users with T2D with different insulin requirements. Methods: This is a retrospective, real-world analysis including MiniMed 780G (MM780G) data uploaded to CareLink Personal (January 2020 to April 2024). Four cohorts were identified based on phenotypes of T2D: (A) users with total daily dose of insulin (TDD) ≥ 100 IU, (B) users with self-reported T2D, (C) users with self-reported T2D and TDD ≥ 100 IU, and (D) users with self-reported T2D and TDD <100 IU. Glycemic outcomes and insulin use were assessed post-AID, pre-AID versus post-AID, and six-month longitudinal post-AID. Results: A total of 26 427 users were included in this study, of which 18 466 in cohort A, 10 795 in cohort B, 2 834 in cohort C, and 7 961 in cohort D. Mean time in range (TIR) was 71.1% ± 12.2 for cohort A, 75.1% ±14.1 for cohort B, 72.2% ± 15.0 for cohort C, and 76.1% ± 13.6 for cohort D. Mean time below range (TBR) <70 mg/dL was ≤1% in all cohorts. The users in cohort C using the recommended optimal settings (glucose target [GT] of 100 mg/dL and active insulin time [AIT] of two hours) had a greater TIR with 78.7% ± 10.8. All cohorts increased ≥10% post-AID compared with pre-AID. Conclusions: The use of this AID is associated with effective therapy outcomes, as indicated by over 70% TIR, and appears to be safe, as demonstrated by a low TBR in a large cohort of real-life users with self-reported T2D and high or low TDD.

2 January 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
ITIsabeau Thijs
Isabeau Thijs
SSSarah E. Siegelaar
Sarah E. Siegelaar
YEYasmine I. Elhenawy
Yasmine I. Elhenawy
Katrien BenhalimaKatrien Benhalima
Katrien Benhalima
OPOrit Pinhas-Hamiel
Orit Pinhas-Hamiel
OCOhad Cohen
Ohad Cohen
Sex‐based disparities in the incidence, prevalence and disease manifestations have been observed across various medical conditions, including type 1 diabetes (T1D). Differences in glycaemic control and quality of life between men and women have been reported, with women experiencing lower rates of glycaemic targets and a higher risk for long‐term complications, particularly cardiovascular disease. Additionally, women face a greater economic and mental health burden related to T1D. This narrative review explores the challenges that complicate glycaemic management in women living with T1D, including hormonal influences during puberty, pregnancy and the (peri‐) menopausal period. We also summarize current available evidence on the safety and efficacy of the MiniMed™ 780G (MM780G) system in addressing these challenges for women living with T1D. Finally, recent real‐world data are reported on the absence of significant sex‐related differences in glycaemic outcomes of over 280 000 real‐world users of the MM780G, across various age groups from childhood and adolescence to the (peri‐) menopausal period.

17 January 2018 in JMIR Preprints
Verified
Preprint
Open access
ITIsabeau Thijs
Isabeau Thijs
LFLibera Fresiello
Libera Fresiello
WOWouter Oosterlinck
Wouter Oosterlinck
PSPeter Sinnaeve
Peter Sinnaeve
FRFilip Rega
Filip Rega
BACKGROUND Wearable technology is finding its way into clinical practice. Physical activity describes patients’ functional status after cardiac surgery and can be monitored remotely by using dedicated trackers. OBJECTIVE The aim of this study was to compare the progress of physical activity in cardiac rehabilitation by using wearable fitness trackers in patients undergoing coronary artery bypass surgery by either the conventional off-pump coronary artery bypass (OPCAB) or the robotically assisted minimally invasive coronary artery bypass (RA-MIDCAB). We hypothesized faster recovery of physical activity after RA-MIDCAB in the first weeks after discharge as compared to OPCAB. METHODS Patients undergoing RA-MIDCAB or OPCAB were included in the study. Each patient received a Fitbit Charge HR (Fitbit Inc, San Francisco, CA) physical activity tracker following discharge. Rehabilitation progress was assessed by measuring the number of steps and physical activity level daily. The physical activity level was calculated as energy expenditure divided by the basic metabolic rate. RESULTS A total of 10 RA-MIDCAB patients with a median age of 68 (min, 55; max, 83) years and 12 OPCAB patients with a median age of 69 (min, 50; max, 82) years were included. Baseline characteristics were comparable except for body mass index (RA-MIDCAB: 26 kg/m²; min, 22; max, 28 versus OPCAB: 29 kg/m²; min, 27; max, 33; P<.001). Intubation time (P<.05) was significantly lower in the RA-MIDCAB group. A clear trend, although not statistically significant, was observed towards a higher number of steps in RA-MIDCAB patients in the first week following discharge. CONCLUSIONS RA-MIDCAB patients have an advantage in recovery in the first weeks of revalidation, which is reflected by the number of steps and physical activity level measured by the Fitbit Charge HR, as compared to OPCAB patients. However, unsupervised assessment of daily physical activity varied widely and could have consequences with regard to the use of these trackers as research tools.